2022
DOI: 10.2147/ccid.s391944
|View full text |Cite
|
Sign up to set email alerts
|

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients

Abstract: Background/Objectives The lip is a unique tissue type that acts as a “barrier” to the mouth and receives many external stimuli. It is also a common symptom in atopic dermatitis. Dupilumab was the first targeted biological drug approved for the treatment of moderate-to-severe atopic dermatitis (AD). There is no real-world clinical data on the use of dupilumab in patients with AD and cheilitis. This retrospective study compared the improvement in skin lesions in AD patients with cheilitis after dupi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…Reduced levels of eosinophils and IgE were found to be associated with a significant improvement in the severity of the disease. Furthermore, Shan et al [129] highlighted the potential role of dupilumab in the treatment of AD with concomitant cheilitis.…”
Section: Novel Treatments Of Ad 821 Biologicsmentioning
confidence: 99%
“…Reduced levels of eosinophils and IgE were found to be associated with a significant improvement in the severity of the disease. Furthermore, Shan et al [129] highlighted the potential role of dupilumab in the treatment of AD with concomitant cheilitis.…”
Section: Novel Treatments Of Ad 821 Biologicsmentioning
confidence: 99%